Additional participants may be enrolled in the Preliminary Safety Cohorts at each dose level to gather additional i nformation on the safety, PK, and PD profile. Approximately 3 participants will be treated at the starting dose levels of BMS-986226 in Part A. During the dose-escalation phase, an adaptive dose-escalation scheme (BLRM for monotherapy and BLRM-Copula for combin ation therapy) employing the escalation with overdose control (EWOC) principle will be used. The method is fully adaptive, makes use of all the information available at the time of each dose assignment, not just data from the current dose level, and directly addresses the et hical need to control the probability of overdosing.